BTL Stock Overview
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Baxter International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.80 |
| 52 Week High | US$78.20 |
| 52 Week Low | US$56.80 |
| Beta | 0.59 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -16.93% |
| 3 Year Change | n/a |
| 5 Year Change | 7.69% |
| Change since IPO | 6.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.4% | -2.5% |
| 1Y | -16.9% | -6.2% | -0.4% |
Return vs Industry: BTL underperformed the German Medical Equipment industry which returned -2.7% over the past year.
Return vs Market: BTL underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| BTL volatility | |
|---|---|
| BTL Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BTL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BTL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1931 | 60,000 | Joe Almeida | www.baxter.com |
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.
Baxter International Inc. Fundamentals Summary
| BTL fundamental statistics | |
|---|---|
| Market cap | €26.37b |
| Earnings (TTM) | -€2.29b |
| Revenue (TTM) | €14.19b |
1.9x
P/S Ratio-11.5x
P/E RatioIs BTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTL income statement (TTM) | |
|---|---|
| Revenue | US$14.74b |
| Cost of Revenue | US$9.07b |
| Gross Profit | US$5.67b |
| Other Expenses | US$8.05b |
| Earnings | -US$2.38b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.71 |
| Gross Margin | 38.49% |
| Net Profit Margin | -16.12% |
| Debt/Equity Ratio | 294.5% |
How did BTL perform over the long term?
See historical performance and comparison